180
Views
4
CrossRef citations to date
0
Altmetric
Srage as Protective Factor in PCOS Development

sRAGE plays a role as a protective factor in the development of PCOS by inhibiting inflammation

, , , , , , & show all
Pages 148-151 | Received 10 Oct 2018, Accepted 14 Jun 2019, Published online: 28 Jun 2019

References

  • Prasad K, Tiwari S. Therapeutic interventions for advanced glycation-end products and its receptor-mediated cardiovascular disease. CPD. 2017;23:937–943.
  • Merhi Z, Irani M, Doswell AD, et al. Follicular fluid soluble receptor for advanced glycation end-products (sRAGE): a potential indicator of ovarian reserve. J Clin Endocrinol Metab. 2014;99:E226–E233.
  • Behren A, Simon C, Schwab RM, et al. Papillomavirus E2 protein induces expression of the matrix metalloproteinase-9 via the extracellular signal-regulated kinase/activator protein-1 signaling pathway. Cancer Res. 2005;65:11613–11621.
  • Chen CG, Tang P, Yu ZT. Effect of HMGB1 on the VEGF-C expression and proliferation of esophageal squamous cancer cells. Zhonghua Zhong Liu Za Zhi. 2012;34:566–570.
  • Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2008;69:634–641.
  • Lazo M, Halushka MK, Shen L, et al. Soluble receptor for advanced glycation end products and the risk for incident heart failure: the atherosclerosis risk in communities study. Am Heart J. 2015;170:961–967.
  • Dozio E, Corradi V, Vianello E, et al. Increased levels of sRAGE in diabetic CKD-G5D patients: a potential protective mechanism against AGE-related upregulation of fibroblast growth factor 23 and inflammation. Mediat Inflamm. 2017;2017:1.
  • Gorry A, White DM, Franks S. Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment. Endocrine.. 2006;30:27–33.
  • Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal. 2001;13:85–94.
  • Heier M, Margeirsdottir HD, Gaarder M, et al. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study. Cardiovasc Diabetol. 2015;14:126.
  • Liu J, Mao J, Jiang Y, et al. AGEs induce apoptosis in rat osteoblast cells by activating the caspase-3 signaling pathway under a high-glucose environment in vitro. Appl Biochem Biotechnol. 2016;178:1015–1027.
  • Onyeagucha BC, Mercado-Pimentel ME, Hutchison J, et al. S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer. Exp Cell Res. 2013;319:2081–2090.
  • Ota K, Yamagishi S, Kim M, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in recurrent pregnancy losses (RPL): possible participation of RAGE in RPL. Fertil Steril. 2014;102:782–789.
  • Jo A-R, Han HS, Seo S, et al. Inhibitory effect of moschamine isolated from Carthamus tinctorius on LPS-induced inflammatory mediators via AP-1 and STAT1/3 inactivation in RAW 264.7 macrophages. Bioorg. Med. Chem. Lett. 2017;27:5245–5251.
  • Na J, Bak D-H, Im SI, et al. Anti-apoptotic effects of glycosaminoglycans via inhibition of ERK/AP?1 signaling in TNF???stimulated human dermal fibroblasts. Int J Mol Med. 2018;41:3090–3098.
  • Sung JY, Chung W, Kim AJ, et al. Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med. 2013;230:59–66.
  • Muth IE, Zschüntzsch J, Kleinschnitz K, et al. HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis. Experimental Neurology. 2015;271:189–197.
  • Onyeagucha BC, Mercado-Pimentel ME, Hutchison J, et al. S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer. Exp. Cell Res. 2013;319:2081–2090.
  • Lian S, Xia Y, Ung T, et al. Prostaglandin E stimulates urokinase-type plasminogen activator receptor via EP2 receptor-dependent signaling pathways in human AGS gastric cancer cells. Mol. Carcinog. 2017; 56:664–680.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.